Merck Serono renews alliance with San Raffaele University on neurodegeneration a decade on

24 July 2014

Merck Serono, the biotech unit of Germany’s Merck KGaA (MRK: DE), says it is continuing its strategic alliance with San Raffaele University and Research Hospital in Milan, Italy, originally established in 2004.

The collaboration is intended to develop preclinical and clinical research projects in neurodegenerative diseases, and will focus on developing new therapies against serious and disabling neurological conditions affecting young adults in particular, such as multiple sclerosis.

Harsukh Parmar, senior vice president and global head of research and early development in immunology and neurology at Merck Serono, said: “Our translational approach to these disease states and combined commitment to expediting the discovery of new therapies aims to improve health outcomes for patients living with unmet medical needs.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK